In the preceding three months, 8 analysts have released ratings for Hims & Hers Health HIMS, presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 5 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 2 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.75, a high estimate of $25.00, and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 31.26% increase from the previous average price target of $16.57.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of Hims & Hers Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Cherny | B of A Securities | Lowers | Buy | $20.00 | $24.00 |
| Ryan MacDonald | Needham | Announces | Buy | $24.00 | - |
| George Hill | Deutsche Bank | Raises | Hold | $23.00 | $16.00 |
| Korinne Wolfmeyer | Piper Sandler | Maintains | Neutral | $18.00 | $18.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $23.00 | $13.00 |
| Jonna Kim | TD Cowen | Raises | Buy | $25.00 | $15.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $18.00 | $16.00 |
| Glen Santangelo | Jefferies | Raises | Hold | $23.00 | $14.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hims & Hers Health's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims & Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Hims & Hers Health's Financial Performance
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Hims & Hers Health showcased positive performance, achieving a revenue growth rate of 51.82% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Hims & Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.21%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's ROE excels beyond industry benchmarks, reaching 3.76%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's ROA stands out, surpassing industry averages. With an impressive ROA of 2.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hims & Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
